Investments in Swiss startups were down over 7 percent in 2020. At the same time, domestic biotech startups managed to secure significantly more funding than in the previous year. These are findings of the Swiss Venture Capital Report.

In 2020, investment in technology-driven Swiss startups was down 7.4 percent to around 2.1 billion Swiss francs. However, the Swiss Venture Capital Report 2021 compiled by the online news portal and the Swiss Private Equity & Corporate Finance Association (SECA) also found that more was invested in startups in the second half of the year than in the same period of the previous record year, 2019. The Report’s authors highlight that donors were concerned with making companies crisis-proof beyond the start-up phase.

According to a press release on, since the first systematic survey in 2012, venture capital investment in Swiss startups has risen from about 300 million francs to more than 2 billion francs today.

Investment in ICT startups fell from about 1.2 billion last year to 720 million francs, but biotech startups were able to increase their equity inflow in 2020 to more than 800 million francs. This equates to growth of 31 percent. The press release states this is due to the global trend of steadily growing biotech investment. The pharmaceutical city of Basel has now displaced the ETH location of Vaud to take second place in the canton rankings behind Zurich. 

Watch the video and learn why bluebird bio set up shop in Greater Zurich: 

Sign up for more news about world-class biotechnology from Greater Zurich

* indicates required

Contact us

Can we put you in touch with a peer company or research institute? Do you need any information regarding your strategic expansion to Switzerland's technology and business center?